BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
Drug developer Legend Biotech Corp. (LEGN.US) on Tuesday reported its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for…
BRIEF: Legend Biotech posts strong fourth-quarter revenue gain
Legend Biotech Corp. (LEGN.US) on Tuesday reported strong double-digit revenue growth in last year’s fourth quarter on solid gains for its core Carvykti cancer treatment, lifting the company to a…
BRIEF: Legend Biotech considers second listing outside U.S.
Cancer treatment maker Legend Biotech Corp. (LEGN.US) is weighing a second listing to complement its existing one in the U.S., with possible venues including Hong Kong, Singapore and London, Bloomberg…
BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
NEWS BRIEF: Legend Biotech’s revenue doubles on big gains for CAR-T treatment
Cancer treatment maker Legend Biotech Corp. (LEGN.US) reported on Friday its revenue more than doubled to $187 million in the second quarter from $73 million a year earlier, while its…
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
A potential sale of Legend Biotech may carry a 30% to 50% premium, which could generate up to 55.8 billion yuan for Genscript based on its 48% stake in the…
GenScript losses shrink on strong growth for cancer cell therapy
The pharma company’s losses narrowed 58% last year, as its life sciences and cell therapy businesses experienced strong growth Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year…
Recent Articles
RELATED ARTICLES
-
BRIEF: Legend Biotech posts strong fourth-quarter revenue gain
- Jacobio Pharma poised to turn a profit from precision cancer drugs
- Time for a new song? Jay Chou-powered Star Plus Legend sings the blues
- Luzhu Biotech braces for make-or-break launch of shingles shot
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- A healthy return: drug spin-off nets Keymed up to $320 million
